CTRI/2017/02/007836Other不适用
A single arm, open label, multicentric, clinical study assessing the efficacy and safety of intramuscular administration of stempeucel® (ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells) in patients with critical limb ischemia due to Buerger’s Disease
试验速览
- 阶段
- 不适用
- 状态
- Other
- 入组人数
- 164
- 试验地点
- 8
- 主要终点
- •Relief of the rest pain
研究概览
简要总结
This study is being conducted as an extension of the phase II clinical trial SRPL/CLI/10-11/001 (CTRI/2011/11/002107). The CDSCO has recommended flexibility for continued clinical study in consultation with ICMR, as per recommendation of Cellular biology based therapeutic drug evaluation committee (CBBTDEC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •a.Buerger’s disease as diagnosed by Shionoya criteria b.Males or females (willing to use accepted methods of contraception during the course of the study) in the age group of 18-65 yrs.
- •c.Established CLI in the study limb, clinically and hemodynamically confirmed as per Rutherford- III-5; d.Patients in Rutherford- III-6 if gangrene extending maximally up to the head of metatarsal but limited to toes (patients with wet gangrene must undergo wound debridement / amputation before screening).
- •e.Patients having infrapopliteal occlusive disease with rest pain and ischemic ulcer/necrosis (patients should have at least one measureable ulcer), who are not eligible for or have failed traditional revascularization treatment as per the investigators judgment (No option patients).
- •f.ABPI ≤ 0.6 or ankle pressure ≤ 50 mm Hg. g.Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent and video consent, abide by the study requirements, and agree to return for required follow-up visits.
排除标准
- •a.Patients with CLI indicated for major amputation during screening b.Atherosclerotic PAD c.Ulcers with exposure of tendon and/bone in the shin region.
- •d.Previous above trans metatarsal amputation in study limb e.Any Lumbar sympathectomy procedure performed less than 90 days prior to the screening f.Patients with gait disturbance for reasons other than CLI g.Diagnosis of diabetes mellitus (type 1 or type 2) h.Patients having left ventricular ejection fraction < 35% i.Patients suffering from clinically relevant peripheral neuropathy j.History of stroke or myocardial infarction k.Patients who are contraindicated for MRA l.Patients with DVT in any limb.
- •m.Patients who have clinically serious and/or unstable inter-current infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy n.Documented terminal illness or cancer or any concomitant disease process with a life expectancy of <1 year o.Patients already enrolled in another investigational drug trial or completed within 3 months or those who have received stem cells in the past p.Patient with known hypersensitivity to the constituents of the stempeucel®– dimethyl sulfoxide (DMSO) or human serum albumin (HSA) q.History of severe alcohol or drug abuse within 3 months of screening r.Hb% < 10 gm% for males, Hb% < 9 gm% for females, serum creatinine ≥ 2mg%, serum Total Bilirubin ≥2mg% s.Pregnant and lactating women t.Patients tested positive for HIV 1 & 2, HCV, HBV, CMV, RPR antibodies and for HBsAg antigen.
结局指标
主要结局
•Relief of the rest pain
时间窗: 6 months and 24 months
•Healing of ulcerations or reduction of ulcer area in the target limb
时间窗: 6 months and 24 months
次要结局
- •Total walking distance(•Major amputation free survival)
研究者
研究点 (8)
Loading locations...
相似试验
撤回
2 期
A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers DiseaseCritical Limb Ischemia Due to Buerger's DiseaseNCT03056742Stempeutics Research Pvt Ltd
Unknown
2 期
Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLCMetastatic Non-small Cell Lung CancerNCT03300115Hangzhou ACEA Pharmaceutical Research Co., Ltd.222
进行中（未招募）
2 期
A Study of Anti-IL-6R mAb Injection in Patients With iMCDNCT05345522Beijing VDJBio Co., LTD.25
招募中
2 期
Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular CarcinomaCadonilimab and LenvatinibNCT06215651Peking Union Medical College Hospital30
已完成
不适用
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric AdenocarcinomaGastroEsophageal CancerGastric CancerNCT04281576NovoCure Ltd.28